MDACC Study No:2007-0772 ( NCT No: NCT00822770)
Title:G-CSF and Plerixafor with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias
Principal Investigator:Marina Konopleva
Treatment Agent:ATG; Busulfan; Filgrastim; Fludarabine; G-CSF; Plerixafor
Study Status:Terminated
Study Description:Unavailable
Hide details for General InformationGeneral Information

Disease Group:Blood And Marrow Transplantation; Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:ATG
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:28 days
Supported By:Genzyme
Return Visit:Up to daily for the first 100 days, every 3 months for one year, yearly
thereafter x 5 years.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Marina Konopleva
Dept:Stem Cell Transplantation and Cellular Therapy
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults